Last edition
News about
Novartis Presents Interim Analysis of atrasentan Phase III Data
Novartis has presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN).
Biocon Signs Exclusive Deal for Commercializing Liraglutide in South Korea with Handok
Biocon Ltd. has signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.
US FDA Grants Priority Review to Sarclisa for Treatment of Transplant-Ineligible NDMM
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab).
Asahi Kasei Medical Completes New Assembly Plant for Planova Virus Removal Filters
Asahi Kasei Medical has announced the completion of its third assembly plant for Planova virus removal filters in Nobeoka, Miyazaki, Japan, and held its completion ceremony.
NS Pharma Reports Preliminary Results of Viltolarsen Phase 3 Clinical Trial
NS Pharma, Inc. has received preliminary analysis results from the global Phase 3 clinical trial (RACER53 study, NCT04060199) of NS-065/NCNP-01.
This expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection so that more adults with chronic diseases like obesity and type 2 diabetes may benefit from these important treatments.
SystImmune Appoints Dr. Jonathan Cheng as New Chief Medical Officer
He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
Orna Therapeutics Acquires ReNAgade to Strengthen Expertise in RNA Therapies
Orna Therapeutics has recently acquired ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months.
Thermo Fisher Scientific Rolls Out Indigenously Developed Air Quality Monitoring Systems
Thermo Fisher Scientific has commenced the manufacturing of Air Quality Monitoring System (AQMS) analyzers in India.
Merck Signs Definitive Deal to Acquire Mirus Bio for USD 600 Million
Merck has signed a definitive agreement to acquire Mirus Bio for USD 600 million.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy